Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmhn sunvozertinib (Zegfrovy) Coverage & Prior Auth…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.742

    Clinical Policy: Sunvozertinib (Zegfrovy)

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.742 alerts

    Get alerted when Policy CP.PHAR.742 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and prior authorization requirements for sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations; applies to members covered by the payer's Commercial, HIM, and Medicaid lines of business.

    Policy Summary
    Payermhn
    PolicySunvozertinib (Zegfrovy) coverage for NSCLC with EGFR exon 20 insertion mutations
    Policy CodePolicy CP.PHAR.742
    Change TypeNo material changes
    Effective DateSep 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis, EGFR exon 20 insertion positivity, prior platinum-based chemotherapy progression, prescriber specialty, and dosing to meet approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    200 mg/daystandard daily dose for NSCLC
    400 mg/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    max with CYP3A inducer
    Adults ≥18age requirement
    EGFR exon 20required biomarker
    150/200 mgavailable strengths

    Coverage Criteria

    inv-01: Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Initial Approval - NSCLC: 1. Diagnosis of recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC); 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is positive for EGFR exon 20 insertion mutations; 5. Zegfrovy is prescribed as subsequent therapy (after prior platinum-based chemotherapy per policy context); 6. Zegfrovy is prescribed as a single agent; 7. Member must use sunvozertinib formulation, if available, unless contraindicated or clinically significant adverse effects occur; 8. Request meets one of the dosing options (see dosing node).

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Dosing constraints (choose one): a) Dose does not exceed 200 mg per day AND 1 tablet per day; OR b) Dose does not exceed 400 mg per day AND 2 tablets per day AND prescriber attests patient cannot avoid concomitant use of a CYP3A inducer (e.g., carbamazepine, rifampin, ritonavir, St. John's wort); OR c) Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use with submitted supporting evidence.

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    inv-02: Continuation Therapy — Covered when ALL of the following are met for continuation

    Covered when ALL of the following are met for continuation:

    Continued Therapy - NSCLC: 1. Currently receiving medication via the benefit, or documentation supports the member has received Zegfrovy for at least 30 days for a covered indication; 2. Member is responding positively to therapy; 3. Member must use sunvozertinib formulation, if available, unless contraindicated or clinically significant adverse effects occur; 4. Zegfrovy is prescribed as a single agent; 5. If request is for a dose increase, the new dose must meet one of the dosing options (a, b, or c).30 days

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Non‑FDA approved indications that are not specifically addressed in this policy are not covered unless the provider submits sufficient documentation of efficacy and safety in accordance with the referenced off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or applicable evidence of coverage documents.

    Use of sunvozertinib (Zegfrovy) for non‑FDA approved indications without adequate supporting evidence as required by the off‑label use policies is considered not authorized for coverage.

    Coding and Dosing

    Covered Diagnosis Codes (illustrative)ICD-10
    ICD-10: C34.*Malignant neoplasm of bronchus and lung (NSCLC - used for member diagnosis coding)
    Maximum daily dosing
    Standard maximum daily dose200 mg/day (NSCLC dosing regimen: 200 mg PO daily)
    Maximum with concomitant CYP3A inducerUp to 400 mg/day if concomitant use with a strong or moderate CYP3A inducer
    Typical administrationOral tablets taken once daily
    Available tablet strengths150 mg and 200 mg tablets (product availability)
    Dose constraints referenced in criteriaInitial and continued therapy require doses to fall within the 200 mg/day standard or the 400 mg/day maximum when interacting CYP3A inducers cannot be avoided

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required. Submit a prior authorization request with supporting documentation that the member meets all applicable initial or continued therapy criteria, including diagnosis of recurrent/advanced/metastatic NSCLC, EGFR exon 20 insertion mutation positivity, prior platinum‑based chemotherapy progression (where applicable), prescriber specialty, age ≥18 years, single‑agent use, and adherence to dosing constraints.

    • Prior authorization must document that the prescribed regimen is FDA‑approved or recommended by NCCN.
    • Dosing constraints: standard 200 mg/day (1 tablet/day) or up to 400 mg/day (2 tablets/day) only with prescriber attestation of inability to avoid CYP3A inducers or supported by guidelines/literature.
    Step Therapy

    Therapeutic alternatives and step considerations

    Therapeutic alternatives listed in Appendix B (e.g., platinum‑based chemotherapy, immune checkpoint inhibitors, taxanes) may be considered per formulary and step‑therapy rules; off‑label or alternative uses require evaluation under the payer's off‑label policies.

    Background

    Sunvozertinib (Zegfrovy) is an epidermal growth factor receptor (EGFR) kinase inhibitor indicated under accelerated approval for adults with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations after progression on platinum‑based chemotherapy. The approved NSCLC dosing regimen is 200 mg orally once daily, with a maximum of 400 mg/day in the setting of concomitant strong or moderate CYP3A inducers; tablets are available in 150 mg and 200 mg strengths. Continued approval may be contingent on confirmatory trials.

    Definitions

    EGFR exon 20 insertion — definition
    Biomarker termEGFR exon 20 insertion
    DefinitionSomatic insertion mutations in exon 20 of the epidermal growth factor receptor (EGFR) gene that are detectable by an FDA-approved test and confer an actionable oncogenic driver for targeted EGFR inhibitor therapy.
    Clinical relevanceRequired biomarker for Zegfrovy indication in locally advanced or metastatic NSCLC after platinum-based chemotherapy progression.

    Initial Therapy Criteria

    inv-13: Initial Therapy — Initial authorization criteria for NSCLC

    Initial authorization criteria for NSCLC:

    Initial Therapy Criteria: 1. Diagnosis of recurrent, advanced, or metastatic NSCLC; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is positive for EGFR exon 20 insertion mutations; 5. Zegfrovy is prescribed as subsequent therapy; 6. Zegfrovy is prescribed as a single agent; 7. Member must use sunvozertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 8. Request meets one of the dosing options: (a) ≤200 mg/day and 1 tablet/day; (b) ≤400 mg/day and 2 tablets/day with prescriber attestation of inability to avoid concomitant CYP3A inducer; or (c) dose supported by practice guidelines or peer-reviewed literature with submitted evidence.

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Continuation Criteria

    inv-14: Continued Therapy — Criteria for continued coverage

    Criteria for continued coverage:

    Continued Therapy Criteria: 1. Member has received Zegfrovy for ≥30 days for a covered indication or is currently receiving medication via the benefit; 2. Member is experiencing clinical benefit/positive response to therapy; 3. Member must use sunvozertinib, if available, unless contraindicated or clinically significant adverse effects are experienced; 4. Zegfrovy is prescribed as a single agent; 5. Any dose increase request must meet one of the dosing options: (a) ≤200 mg/day and 1 tablet/day; (b) ≤400 mg/day and 2 tablets/day with prescriber attestation of inability to avoid concomitant CYP3A inducer; or (c) dose supported by practice guidelines or peer-reviewed literature with submitted evidence.30 days

    Prescribed regimen must be FDA-approved or recommended by NCCN.

    Step Therapy / Sequence of Care

    StepRequirement / descriptionAlternative therapies (Appendix B)
    1
    Zegfrovy (sunvozertinib) is indicated as subsequent therapy for adults (≥18 years) with recurrent, advanced, or metastatic NSCLC positive for EGFR exon 20 insertion mutations after progression on platinum-based chemotherapy; must be prescribed by or in consultation with an oncologist, used as a single agent, and meet dosing constraints (standard 200 mg/day; see dosing exceptions).
    platinum-based chemotherapy (e.g., cisplatin, carboplatin); immune checkpoint inhibitor regimens (e.g., nivolumab ± ipilimumab); taxanes (paclitaxel, albumin-bound paclitaxel, docetaxel ± gemcitabine); gemcitabine ± vinorelbine; pemetrexed

    Quantity Limits

    Zegfrovy (sunvozertinib) — dosing and availability
    Standard daily dose200 mg/day (200 mg PO daily)
    Maximum dose with CYP3A inducerUp to 400 mg/day if concomitant use with a strong or moderate CYP3A inducer
    Available tablet strengths150 mg and 200 mg tablets
    Route of administrationOral (PO)

    Site of Care

    Note

    No site‑of‑care restrictions — documentation required

    No site‑of‑care restrictions are specified; however, providers must submit documentation to support that the member meets the coverage criteria regardless of setting.

    • Ensure documentation demonstrating criteria are met is included with the request even when therapy will be administered at home.
    Policy Summary
    Payermhn
    PolicySunvozertinib (Zegfrovy) coverage for NSCLC with EGFR exon 20 insertion mutations
    Policy CodePolicy CP.PHAR.742
    Change TypeNo material changes
    Effective DateSep 1, 2025
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing diagnosis, EGFR exon 20 insertion positivity, prior platinum-based chemotherapy progression, prescriber specialty, and dosing to meet approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and DosingProvider Actions and RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy / Sequence of CareQuantity LimitsSite of Care
    • Appendix B lists platinum‑based chemotherapy (cisplatin, carboplatin), immune checkpoint inhibitors (e.g., nivolumab ± ipilimumab), taxanes (paclitaxel, albumin‑bound paclitaxel), docetaxel ± gemcitabine, gemcitabine ± vinorelbine, and pemetrexed.
    • Use for non‑FDA approved indications must follow off‑label policies (see CP.CPA.09, HIM.PA.154, CP.PMN.53).
    Documentation Required

    Required clinical documentation

    Provider must submit clinical documentation (such as office notes, laboratory results, and other clinical information) that supports the member's diagnosis of recurrent/advanced/metastatic NSCLC, EGFR exon 20 insertion mutation status, prior therapies (including platinum‑based chemotherapy), current medication list, and any prescriber consultation notes.

    • Include evidence of EGFR exon 20 insertion (testing results) and documentation of progression on or after platinum‑based chemotherapy when applicable.
    • If requesting dose above standard limits, submit prescriber attestation or supporting guidelines/literature per dosing exception criteria.
    Denial Risk

    Documentation and indication‑related denial risk

    Requests lacking adequate documentation that the member meets approval criteria — including absence of diagnostic evidence, missing biomarker test results (EGFR exon 20 insertion), or no documentation of prior platinum‑based chemotherapy when required — may be denied.

    • Non‑FDA indications without sufficient off‑label evidence per the referenced off‑label policies may be considered not authorized.
    • Denials can result if prescriber fails to provide dosing justification or attestation when exceeding standard dosing constraints.